A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

This study is testing a medication called Abemaciclib to see if it can slow down or stop the growth of certain solid tumor cancers. It is designed for patients whose cancer cells have specific genetic changes that help the disease spread.

You may be eligible if you are 18 or older and have an advanced solid tumor that has not responded to other treatments. You must also have specific genetic markers in your cancer—specifically in the CCND, CDK4, or CDK6 genes—confirmed by a laboratory test.

Participants will receive Abemaciclib, a targeted therapy that blocks the proteins cancer cells need to divide and grow. You will be closely monitored by a medical team to see how your body responds to the treatment and to manage any potential side effects.

This study is currently recruiting new participants and is located in Boston, Massachusetts. Please speak with your oncologist to see if this trial might be a good fit for your situation.